- 3. L. G. Vasil'evykh, V. Z. Gorkin, and Z. S. Kagan, Biokhimiya, No. 9, 1542-1550 (1979).
- 4. V. Z. Gorkin, Khim.-Farm, Zh., No. 1, 6-13 (1977).
- 5. É. A. Baumanks, I. É. Kolninya, T. A. Moskvitina, et al. Biokhimiya, No. 8, 1496-1503 (1978).
- D. L. Murphy, S. Zipper, I. C. Campbell, et al., in: Monoamine Oxidase: Structure, Function and Altered Functions (T. P. Singer, R. W. von Korff, D. L. Murphy, eds.), New York (1979), pp. 457-475.
- 7. R. W. Fuller, I. W. Slater, and J. Mills, ibid., pp. 317-333.
- 8. V. Z. Gorkin, L. V. Tat'yanenko, D. M. Krasnokurskaya, et al., Biokhimiya, No. 3, 510-519 (1967).
- 9. M. S. Benedetti, J.-P. Kan, and P. E. Keane, in: Monoamine Oxidase: Structure, Function and Altered Functions (T. P. Singer, R. W. von Korff, D. L. Murphy, eds.), New York (1979), pp. 335-340.
- 10. L. Florvall, A. L. Ask, S. O. Ogren, et al., J. Med. Chem., <u>21</u>, 56-63 (1978).

SYNTHESIS AND STUDY OF THE BIOLOGICAL PROPERTIES OF DERIVATIVES OF 5-CARBOXYMETHYLTHIAZOLIDINE-2,4-DIONE AND OF THIOCARBOHYDRAZIDE

UDC 615.281+615.277.3]:547.497.1].012.1

M. A. Kaldrikyan, A. V. Khekoyan, Yu. Z. Ter-Zakharyan, R. V. Paronikyan, and G. M. Stepanyan

It is known that the thiosemicarbazones of various carbonyl compounds are biologically active substances, and, in particular, possess antiviral properties [1]. The majority of thiosemicarbazones with a high antiviral activity, and also some thiosemicarbazones of  $\alpha$ -(Nheteryl)carbaldehydes with antitumoral activity [2], contain free =NNHC(S)NH<sub>2</sub> groupings. It has been established that the introduction of the latter into a cyclic system leads to heterocyclic compounds with a thiourea skeleton which are interesting subjects of pharmacological investigation [3].

On the basis of the above facts, we have found it desirable to use 4-alkoxybenzaldehydes and 4-alkoxyacetophenones in the synthesis of new derivatives of 5-carboxymethylthiazolidine-2,4-dione and of thiocarbohydrazide with the general formulas:

 $RO \bigotimes_{\substack{n \in \mathbb{N} \\ n \in \mathbb{N} \\ n \in \mathbb{N}}} C_{n} C_{n}$ 

I-XII (for R and R' see Table 2) XIII - XVIII (for R and R' see Table 2)

The main starting materials for the synthesis of compounds (I-XII) were the thiosemicarbazones of 4-alkoxybenzaldehydes and of 4-alkoxyacetophenones obtained by boiling equimolar amounts of the carbonyl compounds with thiosemicarbazide in aqueous alcoholic solution [1, 5]. The latter were caused to react with maleic anhydride in chloroform.

$$\operatorname{RO}\left( \bigcup_{\substack{R'\\R'}} \right) = N - \operatorname{HNCNH}_{2} + \frac{\operatorname{HC} - C \stackrel{\circ}{=} 0}{\operatorname{HC} - C \stackrel{\circ}{=} 0} - - I - \mathbb{Z}.$$

The synthesis of analogous compounds in benzene has been described in the literature [1], but our experiments showed that this always gives mixtures of the initial compounds and the final products. The use of chloroform in place of benzene leads to fairly pure derivatives of 5carboxymethylthiazolidine-2,4-dione with high yields.

The thiocarbohydrazones of 4-alkoxyacetophenones were obtained by the reaction of the 4alkoxyacetophenones with thiocarbohydrazide as described in the literature [6].

$$\begin{array}{c} RO \swarrow CCH_3 + H_2 NHNONINH_2 \longrightarrow III - IIII \\ O S \end{array}$$

A. L. Mndzhoyan Institute of Fine Organic Chemistry of the Academy of Sciences of the Armenian SSR, Erevan. Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 15, No. 5, pp. 62-66, May, 1981. Original article submitted July 9, 1980.

TABLE 1. 4-Alkoxybenzylidenehydrazones and 4-Alkoxy-α-methylbenzylidenehydrazones of 5-Carboxymethylthia-zolidine-2,4-dione

	\$			(	c	Found, %	<b>e</b> /o	Empirical	Calculated, %	id, 0%
Compound	¥	K	rieia, %	י dur	μţ	z	s	formula	z	s
Π	CH <sub>3</sub>	Н	84,3	263-264	0,53	13,39	10,47	C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub> S	13,67	10,43
11	C <sub>s</sub> H <sub>s</sub>	Н	83,1	(decomp.) 253—254	0.58	13.47	9,57	C <sub>14</sub> H <sub>15</sub> N <sub>3</sub> O <sub>4</sub> S	13,07	6 <sup>,61</sup>
III VI	C <sub>3</sub> H, iso-C <sub>3</sub> H,	нн	82,2 75,6	235—236 273—274	0,67 0,69	12,71 12,57	9,20 9,56	C <sub>15</sub> H <sub>17</sub> N <sub>3</sub> O <sub>4</sub> S C <sub>15</sub> H <sub>17</sub> N <sub>3</sub> O <sub>4</sub> S	12,52	9,56 9,56
Λ	C4H	Н	87,1	(decomp.) 242243	0,75	11,72	8,83	C <sub>16</sub> H <sub>19</sub> N <sub>3</sub> O <sub>4</sub> S	12,02	9,17
	iso -C <sub>4</sub> H <sub>9</sub> CH	H CH	72,3 08.0	239-240	0,77	12,48	8,86 0,50	C <sub>16</sub> H <sub>19</sub> N <sub>3</sub> O <sub>4</sub> S	12,02	9,17
VIII	C.H.	CH	84,8	243-244	0.62	12,34	10,00	C15H17NBO4S	12,52	9,56
XI	C <sub>3</sub> H <sub>7</sub>	CH,	85,7	233-234	0,66	12,28	9,65	C16H19N3O4S	12,02	9,17
×;	I ISO-C <sub>3</sub> H,	E.E.	86,9	194-195	0,63	12,34	9,23	CleH19N3C42	11 56	8,89
XIIX	iso -CaHa	ĴĐ	86.0 8	215-216	0,70	11,30	8,80 8,80	C17H21N3O4S	11,56	8,82

Note. According to the literature [4] is 261°C mp of XII.

				-	Found, %	<i>a</i> /o	-	Calcı	Calculated, %
<u>م</u>	Yield, 70	a%	mp, C	Kf	z	s	Empirical formula	z	s
CH CaH CaH CaH iso-CaH iso-CaH iso-CaH	99,1 94,16 89,5 71,1		173—174 173—174 186—188 174—175 142—144 182—183 179—180	0,00,00 0,667 0,6770000000000	23,10 21,59 20,40 20,62 19,62 19,60	13,35 12,40 12,46 12,37 11,77 11,56	C <sub>10</sub> H <sub>14</sub> N <sub>4</sub> OS C <sub>11</sub> H <sub>16</sub> N <sub>4</sub> OS C <sub>12</sub> H <sub>18</sub> N <sub>4</sub> OS C <sub>12</sub> H <sub>18</sub> N <sub>4</sub> OS C <sub>12</sub> H <sub>18</sub> N <sub>4</sub> OS C <sub>13</sub> H <sub>20</sub> N <sub>4</sub> OS C <sub>13</sub> H <sub>20</sub> N <sub>4</sub> OS	23,51 22,20 21,03 19,98 19,98	13,45 12,70 12,40 11,43 11,43

TABLE 2. Thiocarbohydrazones of 4-Alkoxyacetophenones

The purities and individualities of the compounds (I-XVIII) synthesized were checked by chromatography, and their structures were shown by mass spectrometry. In the mass spectra fairly strong peaks of the molecular ions and of a number of fragmentary ions the origin of which confirmed their structure were found.

## EXPERIMENTAL (BIOLOGICAL)

In the chemotherapeutic experiments performed in order to determine the antibacterial and antiviral activities of the compounds synthesized, we used 1050 mice and 340 rats. The antibacterial action of compounds (I-XVIII) was studied by the serial dilution method in a dense nutrient medium (meat-peptone agar, pH 7.2-7.4) with the subsequent seeding of a staphy-lococcus or Flexner dysentry bacillus (microbial load 20 million microbial bodies per 1 ml of medium). The compounds exhibited no antibacterial activity *in vitro* in relation to these organisms.

The chemotherapeutic activity was studied on a model of the generalized staphylococcal infection of white mice caused by intraperitoneal infection with a lethal dose of the culture  $(4 \cdot 10^8 \text{ microbial bodies})$ . The experiments were performed with strains of the cultures sensitive to sulfanilamides, of which two were laboratory strains (Smith and 4-0 strains) and one was a recently-isolated strain (strain 12), and also with one resistant strain (strain 18b). The compound studied was administered simultaneously with the infection. As a control drug we used sulfathiazole (series 130275). The significance of the differences in the survival time of the treated animals as compared with controls was established by means of the alternative form of estimating the reaction with the calculation of the criterion  $\chi^2$  [7].

Of the 5-carboxymethylthiazolidine-2,4-dione derivatives we studied compounds (III, V, IX, and XI) in vivo in chemotherapeutic experiments. When administered to random-bred mice in doses of 2500 and 4000 mg/kg, these compounds caused no changes in the behavior and state of the animals; they were not tolerated in larger doses.

On infection with strain 4-0 of the staphylococcus, all the compounds studied had a therapeutic effect (Table 3). On treatment with compound (V), as with sulfathiazole, a therapeutic effect was observed at all the doses used. At a dose of 1000 mg/kg, the survival rate of the animals was 61%; at this dose, the compound was also active in the infection caused by another laboratory strain — Smith (Table 4). Compounds (III, V, and IX) were active also in the treatment of the infection caused by a recently-isolated staphylococcal strain (strain 12; see Table 2). So far as concerns the infection caused by the resistant

1 0							
Compound	Dose, mg/kg,	Numb <b>er</b> of	Survived	Died	Fotal survival time of the animals		
	once per os	animals	ourvived	Died	absolute, days	% of control	Р
111	500 1000 1500 500	5 10 10 10	0 5 1 4	5 5 9 6 8	0/50 52/100 11/100 41/100	$ \begin{array}{c} 0 \\ 52 \\ 11 \\ 41 \\ \end{array} $	0.01
V IX	1000 1500 500 1000	20 25 5 15	4 12 7 1 7	18 $4$ $8$ .	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		<0,001 <0,1 - <0,01
XI	1500 500 1000	10 5 15	1	9 5 8	10/100 0/50 71/150	10 0 47	
Sulfathiazóle	$     1500 \\     500 \\     1000 \\     15000     $	10 5 10 10	$     \begin{array}{c}       0 \\       7 \\       2 \\       7 \\       6     \end{array} $	8 3 4	21/100 20/50 70/100 60/100	21 40 70 60	$\begin{vmatrix} >0,1\\<0,1\\<0,001\\<0,01\end{vmatrix}$
Control (untreated animals)		15	0	15	0/150	0	

TABLE 3. Chemotherapeutic Action of Thiazolidine-2,4-dione Derivatives in a Staphylococcal Infection of Mice Caused by Staphylococcus aureus, Strain 4-0

<u>Note</u>. Here and in Table 4 the numerator is the number of mousedays in the given group and the denominator is the maximum possible number of mouse-days on observation for 10 days.

n of aureus		Numb <b>er</b>			Fotal survival time of the animals		
Strain of Staph. aureus	C ompound	of animals	Sarvived	Died	absolute, days	% of control	Р
Smith	III V IX XI Sulfathiazole	15 15 15 15 15	1 7 1 2 12	14 8 14 13 3	11/150 70/150 10/150 22/150 120/150	7,3 47 7 15 80	<0,01  <0,001
	Control (untreated animals)	15	0	15	0/150	0	-
12	III V IX XI Sulfathiazole	15 10 15 15 10	10 4 5 3 9	5 6 10 12 1	101/150 40/100 52/150 32/150 90/100	68 40 35 21 90	<0,001 <0,05 0,05 - <0,001
	Control (untreated animals)	15	0	15	0/150	0	
18b	III V IX XI Sulfathiazole	5 10 5 5 10	0 0 0 0	5 10 5 5 10	0/50 0/100 0/50 0/50 0/100	0 0 0 0	
	Control (untreated animals)	10	0	10	0/100	0	

TABLE 4. Chemotherapeutic Action of Compounds (III, V, IX, and XI) in a Dose of 1000 mg/kg on a Staphylococcal Infection

staphylococcus, the compounds studied, like sulfathiazole, had no therapeutic action. A study of compounds (XIII-XVIII) showed that they were more toxic and less active than (I-XII), i.e., the presence of a free =NNHC(S)-NH<sub>2</sub> grouping in the molecule leads to deterioration of the therapeutic action in relation to a staphylococcal infection. Thus, 5-carboxy-methylthiazolidine-2,4-dione derivatives have a low toxicity and under the conditions of integrity of the organism in the treatment of a staphylococcal infection of mice exhibit pronounced chemotherapeutic activity the degree of which is determined by the nature of the compound and of the causative agent. A further search for active compounds in this series is desirable.

The antitumoral activity of the compounds synthesized was determined on two mouse tumors (sarcoma 180 and Ehrlich's ascitic tumor) and two rat tumors (sarcoma 45 and Walker's carcinosarcoma 256). The treatment of the animals after the transplantation of the tumors into them was begun after 24 h (in the case of Ehrlich's ascitic carcinoma) or after 5-6 days (in the case of the solid tumors). The drugs were used in the maximum tolerated doses intraperitoneally (six times for the mice and eight times for the rats). The antiblastic efficiency of the substances tested was evaluated by a known method [8]. It was established that the majority of the compounds studied inhibited sarcoma 45 moderately (40-45%), and compounds (VII-XII) prolonged the life of mice with Ehrlich's ascitic carcinoma by a factor of 1.5-2. The substances possessed no antiblastic activity in relation to sarcoma 180 and Walker's carcinosarcoma.

## EXPERIMENTAL (CHEMICAL)

Mass spectra were taken on an MKh-1303 instrument with direct introduction of the sample into the ionization region at a temperature 40-50°C below the melting point; the energy of the ionizing electrons was 30 eV. Chromatography was performed on Silufol UV-254 plates in ether-ethanol systems [20:1 for (I) and (II); 40:1 for (III) and (IV)]; the ether-acetone systems (40:1) for (V) and (VI); ether-methanol systems [40:1 for (VII) and (VIII) and 80:1 for (IX, X, XI, and XII)]; and the acetone benzene (1:1) system for (XIII-XVIII). The spots were revealed with the aid of UI-1 ultrachemiscope.

<u>4-Alkoxybenzylidenehydrazones</u> and 4-Alkoxy- $\alpha$ -methylbenzylidenehydrazones of 5-Carboxymethylthiazolidine-2,4-dione (I-XII). The appropriate 4-alkoxybenzylidene thiosemicarbazone or 4-alkoxy- $\alpha$ -methylbenzylidenethiosemicarbazone was added to a solution of 1.96 g (0.02 mole) of maleic anhydride in 100 ml of chloroform, and the mixture was boiled in a water bath for 3-4 h. The precipitate formed was filtered off, washed with chloroform, and recrystallized from ethanol (Table 1).

Thiocarbohydrazones of 4-Alkoxyacetophenones(XIII-XVIII). With stirring, 0.05 mole of the appropriate 4-alkoxyacetophenone in 15 ml of methanol was added to a solution of 5.3 g (0.05 mole) of thiocarbohydrazide in 100 ml of hot water, and stirring was continued at 20°C for 12 h. The resulting precipitate was filtered off, washed, and recrystallized from absolute ethanol (Table 2).

## LITERATURE CITED

- 1. A. Krbavćić, M. Plut, A. Polak, et al., J. Med. Chem., 9, 430 (1966).
- F. A. Frensch and E. J. Blanz, Jr., J. Med. Chem., 9, 585 (1966); K. C. Agrawal and A. C. Sartorelli, J. Med. Chem., 12, 771 (1969).
- 3. L. G. Toldi, Khim. Geterotsikl. Soedin., No. 7, 878 (1978).
- 4. Jpn. Patent No. 11,255 (1966); Chem. Abstr., 65, 13716e (1966).
- 5. Y. Bernstein, H. L. Gale, K. Losee, et al., J. Am. Chem. Soc., 73, 906 (1951).
- 6. R. W. Lanon, J. Org. Chem., 34, 756 (1969).
- M. L. Belen'kii, Elements of the Quantitative Evaluation of a Pharmacological Effect [in Russian], 2nd edn., Leningrad (1963), pp. 30-33.
- V. A. Chernov, in: Methods of Experimental Chemotherapy [in Russian], 2nd edn., Moscow (1971), p. 357.

SYNTHESIS AND PHARMACOLOGICAL STUDY OF 2-[(3'-INDOLYL)METHYL]QUINUCLIDINES

UDC 615.31:547.834.4

V. A. Bondarenko, T. K. Trubitsyna, E. E. Mikhlina, M. D. Mashkovskii, and L. N. Yakhontov

In preceding investigations we have shown that in their action on choline- and histaminergic systems, the quinuclidine compounds are much more active than the analogous derivatives of aliphatic or monocyclic amines [1]. In contrast, in the case of adrenergic systems, the transition to quinuclidine derivatives induces a decrease in the pharmacological effect, or even its complete disappearance [2]. It is clear that the above features of the biological activity of the quinuclidine compounds are largely due to the presence in their molecules of a bridgehead nitrogen atom with a descreened free electron pair, which readily interacts with electrophilic centers of choline- and histaminergic receptors, but the bridgehead nitrogen atom is uncapable of entering into similar reactions with the electrophilic centers of adrenoreceptors, which is apparently due to the steric structure features of sections of protein molecule adjoining these centers.

A practical result of the investigations related to the influence of the quinuclidine compounds on the choline- and histaminergic systems was the production and introduction into medicinal practice of original medicinal preparations aceclidine, oxylidine, temequine, phencarol, etc.

From the theoretical and practical points of view, it was very interesting to study the interaction of quinuclidine derivatives with serotoninergic systems. Because of the previously discovered [3] high anti-serotonin activity of certain (3'-quinuclidy1) substituted derivatives of diphenylcarbinols, it could also be assumed that in other series of quinuclidine

S. Ordzhonikidze Scientific-Research Chemical Pharmaceutical Institute, Moscow. Translated from Khimiko-Farmatsevticheskii Zhurnal, No. 5, pp. 67-70, May, 1981. Original article submitted October 4, 1980.